2017 American Transplant Congress
Long-Term Outcome of Antibody-Mediated Rejection Due to Pre-Existing vs. De Novo DSA in Kidney Allograft Recipients.
BackgroundAntibody-mediated rejection (ABMR) can occur in patients with pre-existing anti-HLA donor-specific antibodies (DSA) or in patients who develop de novo DSA. However, how these processes…2017 American Transplant Congress
A Search for a Biomarker Which Predicts Belatacept-Resistant Rejection.
Belatacept, an inhibitor of the CD28-CD80/86 costimulatory pathway, has been associated with a higher acute rejection risk than ciclosporin. We sought to identify a biomarker…2017 American Transplant Congress
A Non-Invasive Urinary Common Rejection Module (uCRM) Gene Expression Score Quantifies and Differentiates Kidney Transplant Injury.
1University of California San Francisco, San Francisco; 2Immucor Inc, Atlanta
We sought to investigate the use of the common rejection module (CRM) genes in the discrimination of AR, BKVN, and stable transplant phenotypes in urine…2017 American Transplant Congress
Gene Expression During Development of Chronic Antibody-Mediated Rejection in Renal Allografts from Non-Human Primates: Validation of Markers Used in Humans and Sequential Changes in Protocol Biopsies.
Background: RNA transcript measurement is a promising adjunct for the diagnosis and classification of antibody-mediated rejection (ABMR), however most technologies require specially processed biopsy samples.…2017 American Transplant Congress
Donor-Derived Cell-Free DNA Predicts Biopsy-Proven Acute Cellular Rejection in Pediatric Kidney Transplant Recipients.
1Surgery, Stanford University, Palo Alto, CA; 2CareDx, Brisbane, CA
Introduction: Surveillance of allograft health is a critical component of post-kidney transplant care. Invasive protocol biopsies are associated with secondary complications and often provide results…2017 American Transplant Congress
Circulating Donor-Specific Memory B Cells (mBc) Discriminates Kidney Transplant Patients with Histological Lesions of ABMR in Absence of Circulating DSA.
Chronic (c)ABMR is a main cause of immune-mediated kidney allograft loss. For its diagnosis, specific histological lesions together with presence of circulating donor-specific alloantibodies (DSA)…2017 American Transplant Congress
Kidney-Specific Immunosuppression without Adverse Systemic Effects.
Purpose: Immunosuppressive therapy is often accompanied by severe adverse effects. To overcome this, the aim of this study was the evaluation of a kidney-specific drug…2017 American Transplant Congress
HLA Class II Molecules Partner with TLR4 to Stimulate Endothelial Cell Activation and Proliferation.
Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, CA
Background: Transplant recipients developing donor specific HLA antibodies (DSA) are at a higher risk for acute and chronic antibody-mediated rejection (AMR). DSA contribute to the…2017 American Transplant Congress
Bortezomib for Late Antibody-Mediated Rejection After Renal Transplantation: A Single Center Experience of 22 Cases.
Despite of tradifional treatments for AMR, such as plasapheresis, ingravenous immunoglobulin, and rituximab, current treatment for antibody-mediated rejection(AMR) after renal transplantation is insufficient. Recently, Bortezomib…2017 American Transplant Congress
Distinctive Molecular Features of Antibody-Mediated versus T-Cell Mediated Rejection in Facial Transplantation.
Brigham and Women's Hospital, Boston, MA
BackgroundA single case of antibody-mediated rejection in a clinical face transplant has been reported worldwide. The availability of repeated allograft biopsies from this patient allowed…
- « Previous Page
- 1
- …
- 111
- 112
- 113
- 114
- 115
- …
- 172
- Next Page »